Understanding how amyloid peptides clump together in Alzheimer's disease
Official title: Pathways and interactions accounting for the oligomerization of amyloid peptides
Funded at New Jersey Institute of Technology · NIH-10804128 · Data updated 2026-11-12
This study is looking at how certain proteins clump together in Alzheimer's disease and how these clumps can harm brain cells, with the hope of finding new ways to stop this process and help prevent the disease.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New Jersey Institute of Technology NIH-funded |
| Lab location | 1 site (Newark, United States) |
| Project start | September 22, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $63,760 |
| NIH project number | 3R15GM148982-01S1 |
| Project ID | NIH-10804128 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for or diagnosed with Alzheimer's disease.
✕Less likely to help
Patients with other forms of dementia unrelated to amyloid aggregation may not benefit from this research.
What this research studies
This research investigates the process by which amyloid peptides aggregate into harmful structures in Alzheimer's disease. It focuses on the interactions between these aggregates and cell membranes, which can lead to cell toxicity. By using advanced molecular dynamics simulations and biochemical experiments, the research aims to uncover the mechanisms behind the formation of these aggregates, particularly how they form on the surface of existing fibrils. The ultimate goal is to develop strategies to inhibit this aggregation, potentially leading to new preventive treatments for Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent or slow the progression of Alzheimer's disease.
How similar studies have gone: Other research has shown promise in targeting amyloid aggregation, indicating that this approach could lead to significant advancements in Alzheimer's treatment.
Where this research is happening
-
New Jersey Institute of Technology
Newark, United States Active
Researchers
- Principal investigator: Dias, Cristiano Luis — New Jersey Institute of Technology
- Study coordinator: Dias, Cristiano Luis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.